The combined recruitment into ProCESS, ARISE and ProMISE is 4210 patients with 3760 patients randomised either to receive EGDT or usual resuscitation. Based on a control event rate ranging from 25%-35%, an 80% power and a two-sided p-value of 0.05, this IPDMA will be able to detect an ARR in 90-day mortality ranging from 4-5% (with no allowance for heterogeneity of treatment effect or clustering of outcomes across the three trials).